{"id":6965,"date":"2025-03-18T18:10:22","date_gmt":"2025-03-18T18:10:22","guid":{"rendered":"https:\/\/stoxpo.com\/?p=6965"},"modified":"2025-03-18T18:10:23","modified_gmt":"2025-03-18T18:10:23","slug":"alpha-cognition-launches-zunveyl-first-oral-alzheimers-drug-approved-by-fda-in-a-decade","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/03\/18\/alpha-cognition-launches-zunveyl-first-oral-alzheimers-drug-approved-by-fda-in-a-decade\/","title":{"rendered":"Alpha Cognition Launches ZUNVEYL, First Oral Alzheimer\u2019s Drug Approved by FDA in a Decade"},"content":{"rendered":"\n

32-Person Sales Team Targets $2 Billion Long-Term Care Market as Company Marks Major Milestone in Alzheimer\u2019s Treatment<\/h4>\n\n\n\n

Alpha Cognition (ACOG) has officially launched ZUNVEYL, the first oral FDA-approved treatment for mild to moderate Alzheimer\u2019s disease in over 10 years. The Vancouver- and Dallas-based biopharmaceutical company announced today that all launch activities were completed on time and on budget, positioning ZUNVEYL for early commercial success.<\/p>\n\n\n\n

With an estimated $2 billion opportunity in the long-term care (LTC) market, Alpha Cognition has deployed a 32-person sales team \u2014 each with an average of 16 years of industry experience and 10 years in LTC \u2014 to drive ZUNVEYL\u2019s adoption among healthcare providers. The drug is now available by prescription in three dosages (5 mg, 10 mg, and 15 mg) at pharmacies nationwide.<\/p>\n\n\n\n

\u201cThe launch of ZUNVEYL is a game-changer in our fight against Alzheimer\u2019s disease,\u201d said Lauren D\u2019Angelo, COO and CCO of Alpha Cognition. \u201cOur team has worked relentlessly to bring this treatment to market \u2014 from building out an industry-leading infrastructure to hiring a top-notch sales team \u2014 all in record time.\u201d<\/p>\n\n\n\n

ZUNVEYL offers a differentiated treatment option for Alzheimer\u2019s patients who have had limited alternatives. The company is also engaging with payers and caregivers to ensure broad access and education for the millions impacted by this progressive neurodegenerative condition.<\/p>\n\n\n\n

Alpha Cognition\u2019s entry into the Alzheimer\u2019s market marks a major step in its mission to provide innovative, accessible solutions for neurodegenerative diseases. With launch activities now complete, the company is focused on ensuring that patients receive ZUNVEYL from day one \u2014 bringing new hope to patients and caregivers alike.<\/p>\n\n\n\n

Read original press release here<\/mark><\/a><\/p>\n\n\n\n

You might like this article:Alphabet Eyes $30 Billion Wiz Acquisition to Bolster Cybersecurity and Cloud Business<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

32-Person Sales Team Targets $2 Billion Long-Term Care Market as Company Marks Major Milestone in Alzheimer\u2019s Treatment Alpha Cognition (ACOG) has officially launched ZUNVEYL, the first oral FDA-approved treatment for mild to moderate Alzheimer\u2019s disease in over 10 years. The Vancouver- and Dallas-based biopharmaceutical company announced today that all launch activities were completed on time […]<\/p>\n","protected":false},"author":2,"featured_media":1127,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[309,359],"tags":[584,585,680,421,416,418,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/6965"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=6965"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/6965\/revisions"}],"predecessor-version":[{"id":6966,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/6965\/revisions\/6966"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1127"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=6965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=6965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=6965"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=6965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}